Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain

Journal of Clinical Psychopharmacology
P MonteleoneM Maj

Abstract

Several candidate genes have been associated with antipsychotic-induced body weight (BW) gain. Because the endocannabinoid system is deeply involved in BW regulation, endocannabinoid genes may have a role in the antipsychotic-induced weight gain. Therefore, we investigated the 1359 G/A (rs1049353) single nucleotide polymorphisms (SNP) of the cannabinoid receptor 1 (CNR1) gene, which codes the endocannabinoid CB1 receptor, and the complementary DNA (cDNA) 385C/A (rs324420) SNP of the FAAH gene, which codes the endocannabinoid degrading enzyme, for their role in BW changes induced by antipsychotic drugs. Eighty-three white psychotic patients who underwent a naturalistic treatment with different antipsychotics (clozapine, olanzapine, risperidone, quetiapine, and haloperidol) and completed a 24-week treatment period were included into the study together with 80 age- and sex-matched white healthy controls. At the 24th week of treatment, 41 patients gained more than 7% of their baseline BW. No significant differences between patients and controls emerged in genotype and allele frequencies of both SNPs. Genotype and allele frequencies of the FAAH cDNA 385C/A SNP but not of the CNR1 1359 G/A SNP significantly differed between subjects ...Continue Reading

References

Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Aug 11, 2000·General Hospital Psychiatry·A I GreenG Blackburn
Feb 14, 2002·Drug and Alcohol Dependence·Lutz G SchmidtMargret R Hoehe
Apr 6, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J C SipeE Beutler
Apr 19, 2005·Obesity Research·Louis PérusseClaude Bouchard
Apr 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Palmiero MonteleoneVincenzo Di Marzo
Feb 16, 2006·JAMA : the Journal of the American Medical Association·F Xavier Pi-SunyerUNKNOWN RIO-North America Study Group
May 11, 2006·The Journal of Clinical Endocrinology and Metabolism·Isabel MatiasVincenzo Di Marzo
Sep 20, 2006·Pharmacogenomics·Daniel J Müller, James L Kennedy
Dec 5, 2006·Trends in Endocrinology and Metabolism : TEM·Isabel Matias, Vincenzo Di Marzo
Jan 12, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Dorit P JensenOluf Pedersen
Jan 17, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M CôtéV Di Marzo
Sep 21, 2007·Neuroscience Letters·Jürgen SeifertManfred Stuhrmann
Nov 19, 2008·Child and Adolescent Psychiatry and Mental Health·Timo Dirk MüllerAnke Hinney
Apr 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Dagmar KoetheF Markus Leweke
Dec 1, 2009·The Psychiatric Clinics of North America·Palmiero MonteleoneMario Maj
Jan 29, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Arun K TiwariDaniel J Müller

❮ Previous
Next ❯

Citations

Jun 27, 2013·Translational Psychiatry·E L NurmiUNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Aug 17, 2011·Pharmacogenomics·Arne J RisseladaToine C G Egberts
Dec 28, 2010·Trends in Molecular Medicine·Christoph U CorrellAnil K Malhotra
Jan 9, 2013·Expert Opinion on Therapeutic Targets·Ioanna VasileiouStamatios Theocharis
Feb 23, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Gavin P Reynolds
Jan 19, 2017·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Eduardo S GouvêaSintia I Belangero
Jun 23, 2011·Human Psychopharmacology·Young-Min ParkHeon-Jeong Lee
Feb 21, 2013·Journal of Clinical Psychopharmacology·Weiping YuRuud van Winkel
Dec 28, 2019·Pharmaceutics·Stefano FortinguerraAlessandro Buriani
Apr 1, 2019·Science China. Life Sciences·Yamin ZhangUNKNOWN Chinese Antipsychotics Pharmacogenomics Consortium
Mar 30, 2021·Frontiers in Psychiatry·Mark R Libowitz, Erika L Nurmi
May 27, 2021·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·José J Martínez-MagañaHumberto Nicolini
Sep 17, 2021·Pharmacogenomics·Pablo ZubiaurFrancisco Abad-Santos
Apr 28, 2011·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Arun K TiwariDaniel J Müller
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Lawrence MaayanC U Correll
The International Journal of Neuropsychopharmacology
Vincenzo De LucaJames L Kennedy
© 2021 Meta ULC. All rights reserved